WHAT TOPICS WERE COVERED?
During this year we made an achievement bringing more than 12000 HCPs into our scientific session about the latest updates on EPL science among MAFLD/MASLD studies.
- To what extent can HRQoL impact clinical outcomes in MAFLD?
- MAFLD - associated metabolic risks in obesity and diabetes
Insights from clinical practice - Early screening of metabolic risk
The pharmacists’ perspective
- Essential phospholipids in the liver health landscape
Clinical evidence - Insights from the SIRIUS project
A population-wide liver disease screening program in Slovakia
- MAFLD
The importance of early identification and intervention - Tools for early detection of metabolic risk in MAFLD
REPLAY EARLIER WEBINARS
Our previous webinars are free to access. Replay them at your convenience to gain more flexibility, deepen your understanding, and foster professional development.
GLOBAL LIVER HEALTH FORUM 2024
MAFLD in Focus : Unveiling Insights from China's RELIEF Study - Insights from APASL 2024
Professor Lai Wei
Metabolic and Toxic Liver Damage in focus – MANPOWER’s Latest Breakthroughs Revealede
Professor Asad I. Dajani
Shedding Light on Genomic, Metabolic, and Phenotypic Effects of Essential Phospholipids on HepaRG
Professor Paola Luciani
Metabolic Comorbidities Unmasked - Redefining MASLD/MASH Impact
Professor Marek Hartleb
Effectiveness of Polyene phosphatidylcholine in metabolic-associated fatty liver disease treatment: A real-world study in China
Professor Wei Lai
Screening and alleviation of burden of MASLD/MAFLD - importance of metabolic and cardiovascular risk
Professor Jose Sollano
Early risk identification of liver disease and MASLD and Place of hepatoprotective adjunctive treatment options
Professor Anamaria Cozma-Petrut
MASLD anno 2024: A rapidly changing landscape
Professor Asad I. Dajani
GLOBAL LIVER HEALTH FORUM 2023
To what extent can HRQoL impact clinical outcomes in MAFLD?
Professor Lai Wei
Essential phospholipids in the liver health landscape – clinical evidence
Professor Asad I. Dajani
MAFLD – the importance of early identification and intervention
Professor Carmen Fierbinteanu
MAFLD-associated metabolic risks in obesity and diabetes – insights from clinical practice
Professor Marek Hartleb
Insights from the SIRIUS project – a population-wide liver disease screening program in Slovakia
Professor Lubomir Skladany
Tools for early detection of metabolic risk in MAFLD
Professor Jose Sollano
Early screening of metabolic risk – the pharmacists’ perspective
Dr. Anamaria Cozma-Petruţ
GLOBAL LIVER HEALTH FORUM 2022
Essential Phospholipids
Prof Dajani
Membrane protection against NAFLD & NASH
Prof An
MAFLD & Covid-19
Prof Sollano
Overview the progress of NASH treatment
Prof Lu
Cardiovascular and metabolic risks of MAFLD - implications for clinical practice
Prof. Hartleb
Potential molecular mechanisms of EPL - insights from EASL 2022
Prof. Fricker
Drug-induced liver injury (DILI) - the importance of early detection
Prof. Mao
Global Liver Institute’s Annual Report
Donna Cryer
GLOBAL LIVER HEALTH FORUM 2021
From NAFLD to MAFLD - the importance of steatosis in the paradigm shift
Prof M Eslam
Detecting steatosis in clinical practice - insights from the EPOCH
Prof L Lazebnik
Essential phospholipids - latest evidence reviewed
Dr A Dajani
Digital trends in healthcare - the potential impact on NALFD
Alexandra Fulford
Early diagnostics of NAFLD – spotting warning signs to prevent progression
Prof N Stefan
Healthcare practitioners’ diagnostic and treatment practice patterns of non-alcoholic fatty liver disease in Poland – a real-world evidence study
Prof M Hartleb
The importance of fast identification and understanding disease progression – key notes for NAFLD management
Prof C Fierbinteanu
Essential phospholipids – efficacy across the spectrum of NAFLD origins
Prof E Sas
Putting MAFLD into perspective – liver-directed hepatoprotective treatment options
Prof J Fan
Hepatic steatosis in MAFLD – importance of early intervention
Prof C Pavlov
Essential phospholipids – new perspectives on the MoA
Prof G Fricker
REPAIR study insights – essential phospholipids across the liver health continuum
Prof A Nersesov
Efforts for early detection and screening of NAFLD, and global burden of NAFLD
Donna Cryer
GLOBAL LIVER HEALTH FORUM 2020
Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights
Prof. Zobair M. Younossi
NAFLD and metabolic comorbidities. Current understanding and perspectives
Prof. Jörn M. Schattenberg
Therapeutic approaches for NAFLD
Prof. Marek Hartleb
Importance of RWE in understanding the current disease landscape: MANPOWER results put into perspective
Prof. Chavdar Pavlov
What does a NAFLD patient journey look like? Importance of HR-QoL
Prof. Huiying Rao
Emerging role of hepatoprotective treatment options
Prof. Jian-Gao Fan
Essential phospholipids. Mechanism of action in liver disease explained
Prof. Boguslaw Okopien
The role of the essential phospholipids in NAFLD continuum
Dr Asad Izziddin Dajani
ACCESS ALL DOCUMENTATION FROM PREVIOUS SUMMITS
Check out our Infographics and Event Books for more details
.2023-01-30-10-21-42.png)